50% off Premium Yearly

NYSE:SOLV
3m completed spinning off healthcare company Solventum today. MMM shares have been challenged by many lawsuits, including over its hearing aids, and some of its businesses have slowed. An exception is Solventum, positing positive organic growth over the past decade. Revenues were $8.2 billion in 2023, but guidance said that 2024 will be a rebuilding year. That said, it's now selling at 11x this year's earnings, cheap. Keep in mind that most spun-offs start off shaky, with those getting initial shares not wanting them. So, buy Solventum gradually over the next 6 months. As for 3M, they paid dearly to settle their lawsuits, so the worst is behind them. Also, they're cutting costs like crazy. Also, Wall Street likes the change in CEOs.
Solventum Corp is a American stock, trading under the symbol SOLV (previously SOLV-N on Stockchase) on the New York Stock Exchange (SOLV). It is usually referred to as NYSE:SOLV or SOLV
In the last year, no analyst issued a Buy, Sell, or Hold rating on SOLV (previously SOLV-N on Stockchase) on Stockchase. Read the latest expert commentary for Solventum Corp.
Solventum Corp was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Solventum Corp.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Solventum Corp.
Solventum Corp is covered by Stockchase experts and is worth watching.
On 2026-06-18, Solventum Corp (SOLV) stock closed at a price of $75.43.